CVAC
CureVac NV
NASDAQ: CVAC · HEALTHCARE · BIOTECHNOLOGY
$4.66
+0.00% today
Updated 2026-04-30
Market cap
$1.05B
P/E ratio
6.96
P/S ratio
14.83x
EPS (TTM)
$0.67
Dividend yield
—
52W range
$3 – $6
Volume
1.1M
WallStSmart proprietary scores
56
out of 100
Grade: C+
Hold
Investment rating
6.7
Growth
B7.8
Quality
B+10.0
Profitability
A+8.3
Valuation
A5/9
Piotroski F-Score
Moderate
3.6
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$5.41
+16.09%
12-Month target
$5.78
+24.03%
Intrinsic (DCF)
$13.95
Margin of safety
+66.59%
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.62 — safe zone
+ Profit margin 182.10% — above average
+ ROE 40.20% — strong efficiency
+ Free cash flow $29.54M — positive
+ 66.59% below intrinsic value
Risks
- Revenue declining -89.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Revenue | $102.99M | $67.42M | $53.76M | $535.18M | $70.74M |
| Net income | $-411.72M | $-249.03M | $-260.17M | $162.19M | $338.04M |
| EPS | — | — | — | — | $0.67 |
| Free cash flow | $-861.03M | $-379.40M | $-323.09M | $83.41M | $29.54M |
| Profit margin | -399.76% | -369.37% | -483.96% | 30.30% | 182.10% |
Peer comparison
Smart narrative
CureVac NV trades at $4.66. representing a P/E of 6.96x trailing earnings. Our Smart Value Score of 56/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 3.62, it sits in the safe zone. TTM revenue stands at $70.74M. with profit margins at 182.10%. Our DCF model estimates intrinsic value at $13.95.
Frequently asked questions
What is CureVac NV's stock price?
CureVac NV (CVAC) trades at $4.66.
Is CureVac NV overvalued?
Smart Value Score 56/100 (Grade C+, Hold). DCF value $13.95.
What is the price target of CureVac NV (CVAC)?
The analyst target price is $5.41, representing +16.1% upside from the current price of $4.66.
What is the intrinsic value of CureVac NV (CVAC)?
Based on our DCF model, intrinsic value is $13.95, a +66.6% margin of safety versus $4.66.
What is CureVac NV's revenue?
TTM revenue is $70.74M.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
3.62 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio14.83x
ROE40.20%
Beta1.84
50D MA$4.97
200D MA$4.85
Shares out0.23B
Float0.18B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—